2000+ oppositions are filed each year at the EPO. Tracking outcome is important since it can influence your generic launch strategy. It also gives an indication as to which companies are eating away your market share.
At a Glance
2660
oppositions filed
930
law firms involved
Top 10 companies facing oppositions
Name
Opposition count
Novartis AG
48
GlaxoSmithKline Biologicals SA
43
Boehringer Ingelheim International GmbH
27
Procter and Gamble Co
21
Nutricia NV
14
Eisai R&D Management Co Ltd
14
Stada Arzneimittel AG
14
Amgen Inc
14
LOreal SA
9
Novo Nordisk AS
9
Top 10 companies who filed oppositions
Name
Opposition count
Generics UK
26
Sandoz
22
Henkel
18
Teva Pharmaceutical Industries
14
JG Oppositions
14
Convatec
12
Sanofi
12
Nicoventures Trading
11
Stada Arzneimittel
11
Maiwald
8
Do you know?
Amylin Pharmaceutical's patent (EP2347762B1) used Exendin to treat diabetes and reducing body weight. However the patent was revoked in Dec-2023 after oppositions raised by not just one but multiple parties.
Contact Us
Top 15 patents facing oppositions
Patent
Applicant
Opposition count
EP3294283B1
Novartis AG
16
EP2959894B1
Novartis AG
12
EP2981255B1
Boehringer Ingelheim International GmbH
10
EP3524595B1
Eisai R&D Management Co Ltd
9
EP3324937B1
Stada Arzneimittel AG
8
EP3694483B1
Procter and Gamble Co
8
EP3448416B1
Novo Nordisk AS
8
EP3578175B1
Amgen Inc
7
EP3067043B1
Novartis AG
6
EP3768304B1
Institut National de la Sante et de la Recherche Medicale INSERM
